Navigation Links
Oncothyreon reports full year and fourth quarter 2007 financial results

BELLEVUE, WA, March 10 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) (the "Company") today reported financial results for the year and quarter ended December 31, 2007. All results are in U.S. dollars and prepared using U.S. GAAP.

Net loss for the year ended December 31, 2007, was $20.3 million or $1.04 per basic and diluted share, compared with $36.4 million, or $2.38 per basic and diluted share in 2006. The substantial decrease in net loss when compared with 2006 primarily reflects the charge of $24.9 million in 2006 related to the acquisition of ProlX Pharmaceuticals, Inc. General and administrative expenses increased by $4.2 million for the year ended December 31, 2007, compared with the year ended December 31, 2006, primarily due to costs associated with the Company's reincorporation into the United States and certain costs associated with a reduction in administrative staff. Revenue from operations for the year ended December 31, 2007, was $3.8 million, compared to $4.0 million in the prior year.

Net loss for the quarter ended December 31, 2007, was $5.2 million or $0.26 per basic and diluted share, compared with $27.1 million or $1.58 per basic and diluted share for the comparable period in 2006. Revenue from operations was $1.9 million, compared to $1.1 million for the same period in 2006. Expenses for the quarter were $7.1 million, compared with $28.7 million for the comparable period in 2006, which included charges of $24.9 million relating to the October 2006 acquisition of ProlX.

As of December 31, 2007, Oncothyreon's cash, cash equivalents and short-term investments were $24.2 million, compared to $28.4 million at the end of 2006, a decrease of $4.2 million, or 14.8 percent. The net decrease reflects operating expenditures of $22.8 million in 2007 offset by $15.8 million in cash received under the Company's collaborative and contract manufacturing agreements. The decrease was also offset by the favorable effect of exchange rate fluctuations on cash and cash equivalents of $1.7 million and short-term investments of $1.9 million.

Financial Guidance

Oncothyreon believes the following financial guidance to be correct as of the date provided. The Company is providing this guidance as a convenience to investors and assumes no obligation to update it.

For 2008, Oncothyreon expects expenses to increase over 2007 as a result of increased manufacturing and process development activities for Stimuvax(R) and more advanced clinical development activity for the Company's small molecule drugs. The Company expects these expenses to be partially offset by increased revenue related to the purchase of Stimuvax clinical supplies by Merck KGaA. As a result, Oncothyreon anticipates that operating cash requirements for 2008 will be between $17 million and $19 million. The Company estimates that it currently has sufficient cash resources to last into the second quarter of 2009.

Business Update

Key achievements for Oncothyreon in 2007 included:

- Initiating a Phase 2 trial of PX-12 in patients with advanced

pancreatic cancer.

- Initiating the START trial, a Phase 3 trial of Stimuvax in patients

with Stage III non-small cell lung cancer, in partnership with

Merck KGaA.

- Successfully manufacturing Stimuvax vaccine and placebo for the START


- Filing an IND and initiating a Phase 1 trial of PX-478 in patients

with advanced solid tumors or lymphomas.

- Signing amended and restated collaboration and supply agreements with

Merck KGaA for Stimuvax, providing for new, near-term milestones, the

first of which was received in December 2007.

- Completing the reincorporation of Biomira into the United States as


Conference Call and Webcast

Oncothyreon's management will discuss the Company's fourth quarter and full year 2007 financial results as well as general business updates during a conference call beginning at 1:30 p.m. PT/ 4:30 p.m. ET today, Monday, March 10, 2008. To listen to a webcast of the discussion, visit

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit

Forward-Looking Statements

In order to provide our investors with an understanding of our current results and future prospects, this release may contain statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include Oncothyreon's expectations regarding expenses related to manufacturing and process development activities and clinical development activities, revenues resulting from Merck's purchase of Stimuvax supplies, and the use and adequacy of cash resources.

Forward-looking statements involve risks and uncertainties related to our business and the general economic environment, many beyond our control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements, including the risks associated with the adequacy of financing and reserves on hand, currency exchange rate fluctuations, changes in general accounting policies, our ability to remediate an identified material weakness in our internal controls, general economic factors, achievement of the results we anticipate from our clinical trials with our products and our ability to adequately obtain and protect our intellectual property rights. Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of our risks and uncertainties, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Additional Information

Additional information relating to Oncothyreon can be found on U.S. EDGAR at and on SEDAR at

Oncothyreon Inc.(1)

Consolidated Statements of Operations Data

(in thousands of U.S. dollars, except share and per share data)


Three Months Ended Year Ended

December 31 December 31

---------------------- ----------------------

2007 2006 2007 2006

---------- ---------- ---------- ----------


Contract research and

development............ $ 29 $ 1,028 $ 631 $ 3,678

Contract manufacturing.. 1,617 - 2,536 -

Licensing revenue from


agreements............. 212 43 528 182

Licensing, royalties

and other revenue...... 80 38 103 119

--------- ---------- ---------- ----------

1,938 1,109 3,798 3,979

--------- ---------- ---------- ----------


Research and

development............ 2,278 2,885 10,011 12,200

Manufacturing........... 1,396 - 2,564 -

General and

administrative......... 3,567 2,298 11,797 7,636

Marketing and business

development............ 26 134 565 587

Depreciation............ 84 56 246 247

In-process research and

development............ - 24,920 - 24,920

Investment and other

loss (income).......... (22) (373) 371 (916)

Interest expense........ 3 2 5 10

Change in fair value of

warrant liability...... (242) (1,238) (1,421) (3,849)

--------- ---------- ---------- ----------

(7,090) (28,684) (24,138) (40,835)

--------- ---------- ---------- ----------

Loss before income taxes.. (5,152) (27,575) (20,340) (36,856)

Income tax recovery

Current................. - 462 - 462

--------- ---------- ---------- ----------

Net loss.................. $ (5,152) $ (27,113) $ (20,340) $ (36,394)

--------- ---------- ---------- ----------

--------- ---------- ---------- ----------

Basic and diluted loss

per share................ $ (0.26) $ (1.58) $ (1.04) $ (2.38)

--------- ---------- ---------- ----------

--------- ---------- ---------- ----------

Weighted average number of

common shares outstanding

(in thousands)........... 19,486 17,133 19,486 15,317

--------- ---------- ---------- ----------

--------- ---------- ---------- ----------

Oncothyreon Inc.(1)

Consolidated Balance Sheets Data

(in thousands of U.S. dollars, except share data)


December 31, December 31,

2007 2006

Cash, cash equivalents and short term

investments.................................. $ 24,186 $ 28,395

Total assets.................................. $ 36,218 $ 33,456

Total long-term liabilities................... $ 12,526 $ 2,328

Shareholders' equity.......................... $ 12,019 $ 27,435

Common shares outstanding..................... 19,485,889 19,485,889

(1) On December 10, 2007, Oncothyreon became the successor corporation to

Biomira Inc. by way of a plan of arrangement effected pursuant to

Canadian law. These financial statements reflect the historical

accounts of Biomira up to December 10, 2007, with the exception of

basic and diluted loss per share and common shares outstanding, which

have been recast to reflect the 6 for 1 common share exchange

effected by the plan of arrangement.

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
2. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
3. Oncothyreon launches new corporate website
4. Oncothyreon to present at BIO CEO & Investor Conference
5. Oncothyreon highlights corporate and clinical objectives for 2008
6. Biomira announces plan to change name to Oncothyreon
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
9. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
10. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
11. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
Post Your Comments:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Sciences today announced the three Winners and six Finalists of the 2017 Blavatnik ... annually by the Blavatnik Family Foundation and administered by the New York Academy ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... genomics analysis platform specifically designed for life science researchers to analyze and ... researcher Rosalind Franklin, who made a major contribution to the discovery of ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia ... be hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” ... pathology adoption best practices and how Proscia improves lab economics and realizes an ...
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
Breaking Biology Technology:
(Date:4/18/2017)... -- Socionext Inc., a global expert in SoC-based imaging and computing solutions, ... which features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ... will be showcased during the upcoming Medtec Japan at Tokyo Big ... Las Vegas Convention Center April 24-27. ... Click here for an image of ...
(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
Breaking Biology News(10 mins):